Real‐life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria

Omalizumab (Xolair) dosing in severe allergic asthma is based on serum IgE and bodyweight. In Australia, patients eligible for omalizumab but exceeding recommended ranges for IgE (30–1500 IU/mL) and bodyweight (30–150 kg) may still receive a ceiling dose of 750 mg/4 weeks. About 62% of patients receiving government‐subsidized omalizumab are enrolled in the Australian Xolair Registry (AXR).

[1]  M. Caruso,et al.  Biologic agents for severe asthma patients: clinical perspectives and implications , 2018, Internal and Emergency Medicine.

[2]  C. Domingo.  Overlapping Effects of New Monoclonal Antibodies for Severe Asthma , 2017, Drugs.

[3]  L. Wood,et al.  Role of Obesity in Asthma: Mechanisms and Management Strategies , 2017, Current Allergy and Asthma Reports.

[4]  A. Haghparast,et al.  Somatic extracts of Marshallagia marshalli downregulate the Th2 associated immune responses in ovalbumin-induced airway inflammation in BALB/c mice , 2017, Parasites & Vectors.

[5]  K. Chung.  Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies , 2016, Journal of internal medicine.

[6]  I. Pavord,et al.  What goes up must come down: biomarkers and novel biologicals in severe asthma , 2015, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[7]  R. O’Hehir,et al.  Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis. , 2015, The journal of allergy and clinical immunology. In practice.

[8]  P. Lowe,et al.  Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE. , 2015, Regulatory toxicology and pharmacology : RTP.

[9]  S. Wenzel,et al.  Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. , 2015, The Journal of allergy and clinical immunology.

[10]  H. Watz,et al.  Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table. , 2014, Pulmonary pharmacology & therapeutics.

[11]  S. Walker,et al.  Omalizumab for asthma in adults and children. , 2014, The Cochrane database of systematic reviews.

[12]  J. Fahy.  Type 2 inflammation in asthma — present in most, absent in many , 2014, Nature Reviews Immunology.

[13]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[14]  W. Busse,et al.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. , 2013, American journal of respiratory and critical care medicine.

[15]  T. Casale,et al.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.

[16]  P. Gergen,et al.  Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. , 2013, The journal of allergy and clinical immunology. In practice.

[17]  M. Humbert,et al.  A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. , 2013, Chest.

[18]  I. Pavord,et al.  Omalizumab: NICE to USE you, to LOSE you NICE , 2012, Thorax.

[19]  S. de la Motte,et al.  Omalizumab Protects against Allergen- Induced Bronchoconstriction in Allergic (Immunoglobulin E-Mediated) Asthma , 2012, International Archives of Allergy and Immunology.

[20]  S. Wenzel.  Asthma phenotypes: the evolution from clinical to molecular approaches , 2012, Nature Medicine.

[21]  K. Chung,et al.  Corticosteroid insensitivity in severe asthma: significance, mechanisms and aetiology , 2010, Internal medicine journal.

[22]  P. Gibson,et al.  Inflammatory phenotypes in adult asthma: clinical applications , 2009, The clinical respiratory journal.

[23]  S. Holgate,et al.  Safety and tolerability of omalizumab , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[24]  J. Bousquet,et al.  Predicting and evaluating response to omalizumab in patients with severe allergic asthma. , 2007, Respiratory medicine.

[25]  Linda Abetz,et al.  Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. , 2006, Respiratory medicine.

[26]  I. Pavord,et al.  Multi‐dimensional phenotyping: towards a new taxonomy for airway disease , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[27]  T. Casale,et al.  Omalizumab in asthma , 2005, Clinical reviews in allergy & immunology.

[28]  Klas Svensson,et al.  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.

[29]  J Bousquet,et al.  Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.

[30]  Charles A. Johnson,et al.  Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma , 2003, Current medical research and opinion.

[31]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[32]  A. Buist,et al.  Validation of a standardized version of the Asthma Quality of Life Questionnaire. , 1999, Chest.

[33]  G H Guyatt,et al.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire. , 1994, Journal of clinical epidemiology.